CJC-1295 vs Hexarelin: Research Comparison

Research use only. This compound is sold strictly for laboratory and in-vitro research. It is not a drug, supplement, food, or cosmetic, is not approved by the FDA, is not intended to diagnose, treat, cure, or prevent any disease, and is not for human or animal consumption. Dosing figures are reference values from the research literature for laboratory models only.

CJC-1295 vs Hexarelin at a glance

	CJC-1295	Hexarelin
Also known as	with or without DAC	potent GHRP
Category	Growth Hormone & Muscle	Growth Hormone & Muscle
Format	SubQ	SubQ
Research level	Beginner	Advanced
Research sizes	2 mg vial, 5 mg vial	2 mg vial, 5 mg vial
In one line	A GHRH analog studied for growth-hormone-release research, with and without DAC.	The most potent GHRP in the catalog, studied for strong growth-hormone release.

What is CJC-1295?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is studied in two forms: "no DAC" (also called Mod GRF 1-29), which is short-acting, and "with DAC" (Drug Affinity Complex), which binds albumin for a markedly longer half-life in research models.

CJC-1295 research focuses on stimulation of the pituitary to release growth hormone in pulses. The DAC version extends the active window, while the no-DAC version produces a sharper, shorter pulse often studied alongside a GHRP such as Ipamorelin for synergistic release.

What is Hexarelin?

Hexarelin is a synthetic hexapeptide and one of the most potent growth-hormone-releasing peptides studied in research, with reported activity beyond GH release including cardiovascular-tissue signaling.

Hexarelin strongly activates the GH-secretagogue receptor. Research notes desensitization with continuous exposure and increases in prolactin and cortisol, so cycled study designs are common.

Key research differences

The two are best understood by what each is studied for. CJC-1295: The DAC form trades fewer administrations for a longer, flatter profile; the no-DAC form is studied for sharper, more physiologic pulses. Choice depends on the research kinetics of interest. Hexarelin: Hexarelin is the most potent GHRP studied here but with the most off-target signaling and desensitization, contrasting with the gentler Ipamorelin.

How researchers choose between them

Because CJC-1295 and Hexarelin both sit in the growth hormone & muscle category, the choice is a research-design question: match the compound to the exact signal or endpoint your model targets, and in many protocols the two are studied in parallel or in sequence rather than as either/or. Whichever you select, compare on verified quality: both are third-party tested to a 99%+ purity target with a COA on request.

Order CJC-1295 or Hexarelin

Both available research-grade with a COA on request.

See pricing & sizes

Frequently asked questions

What is the difference between CJC-1295 and Hexarelin?

CJC-1295 a GHRH analog studied for growth-hormone-release research, with and without DAC; Hexarelin the most potent GHRP in the catalog, studied for strong growth-hormone release. Both are growth hormone & muscle research peptides. Both are research-use-only.

Can CJC-1295 and Hexarelin be studied together?

Yes - within the same category they are often studied in parallel or sequence to compare or combine effects. Any combination work is laboratory research only.

Which is better, CJC-1295 or Hexarelin?

Neither is universally "better" - the right choice depends on the research question. Match the compound to your model's target signal, and compare suppliers on verifiable third-party purity, not sticker price.

All comparisons · CJC-1295 · Hexarelin · CJC-1295 cost

External references: Peptide (Wikipedia) · U.S. Food and Drug Administration

Both compounds are sold for laboratory and research use only and are not for human or animal consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.